CD274 and non-small cell lung carcinoma: The primary endpoint was investigator-assessed disease-free survival (DFS) evaluated in the stage II-IIIA PD-L1 positive population, in all the patients with stage II-IIIA, and in the ITT population including all randomized patients with stage IB-IIIA NSCLC.